Impact of Rifaximin on Liver Fibrosis in HIV-Infected Patients With Liver Disease
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 13 Jul 2018
At a glance
- Drugs Rifaximin (Primary)
- Indications Hepatic encephalopathy; Hepatic fibrosis; Liver cirrhosis
- Focus Therapeutic Use
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
- 10 Jun 2017 Biomarkers information updated
- 25 Sep 2015 Planned End Date changed from 1 Sep 2013 to 1 Sep 2015 as reported by ClinicalTrials.gov.